UK’s NICE Price Discounts ‘Pass Risk To Patients’
Executive Summary
Health technology appraisal mechanisms like discounts do nothing to address a lack of clinical evidence and simply transfer the uncertainty to patients, NICE’s recent annual conference heard.
You may also be interested in...
UK NICE To Pharma Firms: Up Your Game In Horizon Scanning
Pharmaceutical companies must play a fuller part in planning for health technology appraisals by NICE, which has resource limitations and cannot do everything that companies might expect of it, a recent workshop in London heard.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.